drugset / Trial / NCT04901169

Angiotensin II in Liver Transplantation

NCT04901169

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.

Timeline

Start
2022-06-28
Primary completion
2026-03-18
Completion
2027-03-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Angiotensin II Peptide Intravenous

Indications